Sanofi (NYSE:SNY) was supposed to be a relatively solid Big Pharma company in 2013. True, the company is going through some pressures from patent expirations and internal drug development issues have created a soft spot for growth, but Sanofi's strong emerging market exposure was supposed to help, as was the fact that about one-third of the company's revenue comes from non-branded drug businesses.
Instead, Sanofi delivered a surprisingly large miss for the second quarter, a miss that means a little more in the typically more predictable Big Pharma space. While it may be true that problems in Brazil were a large part of the reported miss, worse than expected results in ex-Brazil emerging markets, vaccines, and animal health, coupled with higher than expected SG&A spending to support new launches, has reset expectations to a lower level. Although Sanofi shares are not overvalued today and the company could demonstrate fairly quickly that Q2 results were just an aberration, it's harder to make a forceful pro-Sanofi argument today.

SEE: Evaluating Pharmaceutical Companies
A Lot Of Ugly In Q2
Sanofi's second quarter report makes for pretty ugly reading. Revenue fell 10% as reported (and 6% in constant currency), leading to a 5% miss relative to expectations – likely to be the biggest deviation (good or bad) from the average for the sector this quarter. Pharmaceutical sales (net of Genzyme) were down about 12% this quarter, though Genzyme products were up a strong 21%. Everything else was down as well – Consumer was down 1%, Generics were down 36% and 35% below expectations (though up 10% net of Brazil), Vaccines were down 3% (missing by 6%), and Animal Health was down 9% (also missing by 6%).
There wasn't much good news down the line either. Gross margin fell four and a half points, missing the average expectation by two and a half points. Operating income plunged 28% (with operating margin falling more than six points), missing estimates by more than 20%, as the company needed heavier SG&A spending to support the diabetes business and upcoming product launches.
All told, EPS ended up 15% below expectations, as a lower tax rate helped gain back some of the poor operating performance. Now it's true that a large charge in Brazil tied to channel-stuffing had a major impact on the quarter, but it doesn't explain all of the miss – emerging market growth was still only 5% excluding the Brazil problem, and that was below the double-digit target.

SEE: How To Evaluate The Quality Of EPS
A Few Bright Spots Stand Out
Assuming that the issue in Brazil really was just due to local management mistakes and perhaps a lack of observation/supervision from HQ, there were some good points to highlight in Sanofi's report.
For starters, even with serious competition from Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) in the insulin space, Lantus remains a star – growing 18% in constant currency and contributing more than 17% of the company's revenue. Secondly, Genzyme continues to perform quite well – revenue was up 21% this quarter, and it looks as though Sanofi/Genzyme is taking some share from Shire (Nasdaq:SHPG) in rare diseases.
The Pipeline – Underwhelming, Or Underappreciated?
Sanofi definitely needs to add some oxen to its wagon team. Although Lantus and the rare disease/Genzyme platform are growing well, the oncology business is withering away into nothing (down 49%), and it's largest drugs (Plavix, Lovenox, and Avapro) are off-patent and declining at double-digit rates.
The new MS franchise should help, as Lemtrada is expected to get FDA approval in the fourth quarter of this year and could be a $1B+ drug even with competition from Biogen Idec (Nasdaq: BIIB). Investors can also look forward to Phase III data on Sanofi's PCSK9 cholesterol drug in the third quarter (a potential multi-billion dollar drug, though facing competition from the likes of Amgen (Nasdaq:AMGN) and Pfizer (NYSE:PFE)), Phase III data on sarilumab in rheumatoid arthritis in the first half of 2013, and FDA approval of Lxymia later in 2013.
Lemtrada and '553 (the PCSK9 drug) look like solid winners, but beyond that it gets fuzzier. Sanofi does not have the same quality of pipeline as many of its Big Pharma peers (though it may well be underrated), and it hasn't been as aggressive in addressing it as, say, AstraZeneca (NYSE: AZN). With that, any disruption to the Lemtrada or cholesterol businesses could have an outsized impact, and I would imagine Sanofi would be considering partnerships or M&A if biotech valuations ease off a bit.
The Bottom Line
I've been pretty bullish on Sanofi, but the issues in Brazil and potential fraud problems in China are frankly embarrassing and run counter to the notion that Sanofi's management team has cleaned up the mistakes of the past. Although I think management has gotten a great deal more prudent and realistic about pipeline management, the reality is that Sanofi needs more depth and breadth in its branded drugs, as well as consistent solid performance from its emerging markets businesses.
I still expect Sanofi to produce long-term free cash flow growth well above average (more than 6%), but that's worth about $52 per share today. While there aren't many bargains in Big Pharma, and Sanofi is undervalued, investors considering the shares need to be patient and understand that the next couple of quarters could still be a little shaky.
At the time of writing, the author did not own shares of any company mentioned in this article.

Related Articles
  1. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  2. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  3. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  4. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  5. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  6. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  7. Professionals

    What to do During a Market Correction

    The market has what? Here's what you should consider rather than panicking.
  8. Mutual Funds & ETFs

    ETF Analysis: Vanguard Mid-Cap Value

    Take an in-depth look at the Vanguard Mid-Cap Value ETF, one of the largest and most popular mid-cap funds in the U.S. equity space.
  9. Mutual Funds & ETFs

    ETF Analysis: Schwab US Broad Market

    Take an in-depth look at the Schwab U.S. Broad Market ETF, an incredibly low-cost fund based on a wide selection of the U.S. equity market.
  10. Professionals

    Tips for Helping Clients Though Market Corrections

    When the stock market sees a steep drop, clients are bound to get anxious. Here are some tips for talking them off the ledge.
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  3. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  4. Earnings Per Share - EPS

    The portion of a company's profit allocated to each outstanding ...
  5. PT (Perseroan Terbatas)

    An acronym for Perseroan Terbatas, which is Limited Liability ...
  6. Ltd. (Limited)

    An abbreviation of "limited," Ltd. is a suffix that ...
  1. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  2. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  3. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  4. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  5. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
  6. How does the role of Medicare/Medicaid affect the drugs sector in the U.S.?

    Medicare and Medicaid have enormous influence on the pharmaceutical, or drugs, sector in the United States. For instance, ... Read Full Answer >>

You May Also Like

Trading Center

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!